The 2024 KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD) introduces the most significant updates since 2012. The new recommendations reflect major advances in risk stratification, GFR estimation, and disease-modifying therapies that meaningfully slow CKD progression and reduce cardiovascular risk.
This summary highlights the essential changes relevant to primary care, internal medicine, and family medicine clinicians—focusing on areas that impact day-to-day outpatient practice.
1. Refined CKD Classification & Risk Assessment
- KDIGO continues to classify CKD using cause, GFR category, and albuminuria category (C-G-A).
- Stronger emphasis is placed on risk over thresholds. Clinicians are encouraged to use validated kidney failure prediction tools to guide:
- Referral timing
- Follow-up frequency
- Medication intensity
- Care coordination
- Serum cystatin C is more strongly recommended when creatinine-based eGFR may be inaccurate (e.g., extremes of body size, reduced muscle mass, specific comorbidities). Cystatin-C–based eGFR or combined eGFRcr-cys improves diagnostic precision and medication dosing accuracy.
2. Expanded Role of Disease-Modifying Therapies
SGLT2 Inhibitors
One of the most practice-changing updates:
- KDIGO endorses the use of SGLT2 inhibitors in CKD even without diabetes, provided GFR and albuminuria criteria are met.
- Evidence continues to show benefit for slowing CKD progression, reducing HF hospitalizations, and lowering cardiovascular events.
Renin–Angiotensin System Inhibitors (ACEi/ARB)
- Remain first-line for CKD with albuminuria and for hypertension management.
- Continue even with modest increases in creatinine unless contraindications arise.
Statins
- Recommended for adults with CKD not on dialysis, particularly those ≥50 years or with additional ASCVD risk factors.
3. More Holistic, Multidisciplinary CKD Care
KDIGO highlights the importance of team-based, patient-centered care, including:
- Nutritional counseling (especially sodium and protein intake guidance)
- Medication review to minimize nephrotoxic exposures
- Cardiovascular risk management
- Psychological and social support
- Early education regarding kidney failure treatment options and transplant readiness
The guideline encourages care models that support shared decision-making and improved long-term outcomes.
4. Updated Implementation Tools
- Recommendations are paired with Practice Points where evidence is emerging but expert consensus supports action.
- A detailed research agenda outlines priority gaps in CKD science—helping clinicians anticipate future shifts in best practice.
5. Practical Outpatient Takeaways
For clinicians managing CKD in primary care or internal medicine:
- Order both eGFR and urine ACR routinely for staging and risk stratification.
- Use cystatin C when creatinine-based estimates are unreliable.
- Consider SGLT2 inhibitors broadly, independent of diabetes status.
- Maintain RAAS blockade and statin therapy where indicated.
- Apply risk calculators to inform follow-up intervals and nephrology referral.
- Integrate a multidisciplinary approach, particularly for nutrition, CV risk, and medication optimization.
Learn More — CME Travel Academy
At CME Travel Academy, we create evidence-based, guideline-driven continuing medical education specifically for clinicians in family medicine and internal medicine.
Our courses:
- Focus on chronic disease management including CKD using the newest clinical guidelines
- Incorporate research-backed retention strategies, including 12-month spaced repetition
- Provide one-page point-of-care references for immediate clinical application
- Are available online or at destination-based, in-person CME conferences
If you want deeper, practical training on CKD, heart failure, asthma, diabetes, hypertension, and more—visit CME Travel Academy to explore upcoming courses and our travel-friendly CME conferences.